Published in Neuropathol Appl Neurobiol on December 29, 1978
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 1.63
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A (2005) 1.61
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.50
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res (2009) 1.20
The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry (1982) 1.15
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res (2007) 1.04
Genetic therapy for the nervous system. Hum Mol Genet (2011) 1.03
A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem (2009) 0.98
Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging (2007) 0.97
Genetic risk factors in Alzheimer's disease. Mol Pathol (1998) 0.97
Basal forebrain control of wakefulness and cortical rhythms. Nat Commun (2015) 0.94
The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem (2009) 0.94
Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: A Preliminary anti- Alzheimer's study. Lipids Health Dis (2015) 0.93
Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry (2005) 0.91
Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol (2011) 0.91
A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra (2011) 0.90
Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study. Prim Care Companion J Clin Psychiatry (2005) 0.89
Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease. Front Physiol (2012) 0.89
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther (2013) 0.88
Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol (2008) 0.88
Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res (2013) 0.87
Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease. PLoS One (2007) 0.87
Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin. Cell Mol Neurobiol (2001) 0.87
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 0.86
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. Curr Ther Res Clin Exp (2003) 0.85
Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. PLoS One (2013) 0.84
Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors. Acta Pharmacol Sin (2012) 0.84
Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm (Vienna) (2008) 0.83
Selective hippocampal cholinergic deafferentation impairs self-movement cue use during a food hoarding task. Behav Brain Res (2007) 0.83
Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors? Br J Pharmacol (2013) 0.82
Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase. Antiinflamm Antiallergy Agents Med Chem (2013) 0.82
EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract (2007) 0.82
BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia. J Neural Transm (Vienna) (2010) 0.81
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci (2003) 0.80
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 0.80
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics (2009) 0.80
Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease. J Neural Transm (Vienna) (2015) 0.79
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics (2009) 0.79
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study. PLoS One (2014) 0.79
Sympathetic sprouting in visual cortex stimulated by cholinergic denervation rescues expression of two forms of long-term depression at layer 2/3 synapses. Neuroscience (2010) 0.79
Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. Biochim Biophys Acta (2011) 0.79
Biochemical differentiation of cholinesterases from normal and Alzheimer's disease cortex. Curr Alzheimer Res (2012) 0.78
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. Prim Care Companion CNS Disord (2013) 0.78
Anti-cholinesterase activity of the standardized extract of Syzygium aromaticum L. Pharmacogn Mag (2014) 0.78
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease. Front Neurosci (2016) 0.77
Is the distinction between Alzheimer's disease and vascular dementia possible and relevant? Dialogues Clin Neurosci (2003) 0.76
Alzheimer's disease: recent advances and future prospects. Br Med J (Clin Res Ed) (1983) 0.76
A Platform for Screening Potential Anticholinesterase Fractions and Components Obtained from Anemarrhena asphodeloides Bge for Treating Alzheimer's Disease. Evid Based Complement Alternat Med (2014) 0.75
Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease. J Chromatogr A (2008) 0.75
Determination of allelic expression of SNP rs1880676 in choline acetyltransferase gene in HeLa cells. Neurosci Lett (2013) 0.75
Modulatory role of simvastatin against aluminium chloride-induced behavioural and biochemical changes in rats. Behav Neurol (2015) 0.75
Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease. Neuropathology (2015) 0.75
Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents. Chem Cent J (2013) 0.75
Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. Bioorg Med Chem Lett (2016) 0.75
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging (2017) 0.75
Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease. Front Aging Neurosci (2014) 0.75
Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease. Am J Neurodegener Dis (2014) 0.75
Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases. Cell Mol Neurobiol (2003) 0.75
Rivastigmine improves isolation rearing-induced prepulse inhibition deficits via muscarinic acetylcholine receptors in mice. Psychopharmacology (Berl) (2015) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry (1968) 18.69
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Observations on the brains of demented old people. J Neurol Sci (1970) 6.99
Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature (1982) 4.93
Observations on the brains of non-demented old people. J Neurol Sci (1969) 4.06
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
Staging and natural history of cerebrovascular pathology in dementia. Neurology (2012) 2.61
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
Prevalence rates of dementia in an ageing population: are low rates due to the use of insensitive instruments? Age Ageing (1990) 2.45
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci (1990) 2.24
Correlation between scores for dementia and counts of 'senile plaques' in cerebral grey matter of elderly subjects. Nature (1966) 2.23
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Autism as a disorder of neural information processing: directions for research and targets for therapy. Mol Psychiatry (2004) 2.19
The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci (1977) 2.07
Histochemical aspects of five limb muscles in old age. An autopsy study. J Neurol Sci (1971) 2.03
The effects of ageing and of cachexia upon skeletal muscle. A histopathological study. J Neurol Sci (1969) 2.00
Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology (1999) 2.00
Necropsy evidence of central cholinergic deficits in senile dementia. Lancet (1977) 1.97
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91
Letter: Unusual cardiac and neurological reactions to narcotics. Lancet (1973) 1.90
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000) 1.85
A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res (1981) 1.85
Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci (1977) 1.83
Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci (1981) 1.78
Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet (1994) 1.77
Radiation myelitis of the dorsolumbar spinal cord. Radiology (1969) 1.64
Granulovacuolar degeneration of hippocampal pyramidal cells. J Pathol (1972) 1.59
A neuropathological study of vascular factors in late-life depression. J Neurol Neurosurg Psychiatry (2001) 1.53
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci (1983) 1.51
Data on the distribution of fibre types in five human limb muscles. An autopsy study. J Neurol Sci (1971) 1.51
The contemporary natural history of mental disorder in old age. Br J Psychiatry (1982) 1.50
Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med (1992) 1.49
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain (1999) 1.48
The extensor digitorum brevis: histological and histochemical aspects. J Neurol Neurosurg Psychiatry (1972) 1.47
Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry (2001) 1.44
Central pontine myelinolysis. Two cases with associated electrolyte disturbance. Q J Med (1976) 1.40
Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer (1992) 1.36
Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet (1986) 1.35
The cholinergic hypothesis--ten years on. Br Med Bull (1986) 1.31
Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. Neuropathol Appl Neurobiol (2006) 1.29
Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav (2002) 1.28
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol (1994) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology (2003) 1.28
An evaluation of lymphadenectomy in the treatment of malignant testicular germ cell neoplasms. J Urol (1969) 1.26
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci (1991) 1.24
Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology (2000) 1.22
Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease. J Neurol Sci (1977) 1.20
Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull (1988) 1.20
The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry (1994) 1.18
An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology (1994) 1.18
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Clinically and neuropathologically distinct form of dementia in the elderly. Lancet (1989) 1.16
Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett (1982) 1.14
Subacute "poliomyelitis" and Hodgkin's disease. J Neurol Sci (1969) 1.11
Amyloid and senile plaques and cerebral blood vessels. A semi-quantitative investigation of a possible relationship. J Neurol Sci (1983) 1.11
Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) (1981) 1.11